Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | PE01; PEO-1; PEO |
| Species | Human |
| Cat.No | ABC-TC5590 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
| Disease | Ovarian Cancer |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
PEO1 is an adherent cell line originally isolated from the peritoneal ascites of a patient afflicted with a hereditary heterozygous BRCA2 mutation (5193C>G (Y1655X)) and diagnosed 
with poorly differentiated serous ovarian adenocarcinoma. This cell line was obtained before the tumor developed resistance to chemotherapy, notably cisplatin, 5-fluorouracil, and chlorambucil. PEO1 exhibits tumorigenic properties in immunologically-deprived CBA mice and demonstrates robust growth in semi-solid agar medium. When subcultured, PEO1 follows a split ratio ranging from 1:4 to 1:10, with a doubling time of approximately 37 hours.
Why choose PEO1 from AcceGen?
PEO1 cell line from AcceGen exhibits high viability and quality due to its cultivation under optimal conditions, ensuring sterility. It has been cryopreserved using advanced techniques and undergoes rigorous quality control measures to maintain its integrity and reliability for research purposes.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
PEO1 cell line serves as a valuable tool in diverse research domains, notably in the realms of cancer, drug discovery, and development. Within the cancer field, it offers insights into the mechanism of estrogen action on ovarian adenocarcinoma tumor cells. Moreover, PEO1 is instrumental in the study of the efficacy and toxicity of estrogen agonists, making it a crucial asset in drug development efforts targeting ovarian adenocarcinoma and related conditions.
